Clinical Trial Update: Aromasin® Interventional Study Of Early Invasive Breast Cancer Patients In China [Phase 4]

View source ↗

Summary

Phase 4 interventional study of Aromasin in early invasive breast cancer patients in China has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Breast Neoplasms

Drugs mentioned

• Aromasin (exemestane)

Snippet

Sponsor: Pfizer | Conditions: Breast Neoplasms | Phase 4 | Status: COMPLETED | Results posted: 2020-10-12